Capstan Therapeutics to Participate in Upcoming Investor Conferences

SAN DIEGO & PHILADELPHIA–(BUSINESS WIRE)–Capstan Therapeutics, Inc., a biotechnology company dedicated to advancing in vivo reprogramming of cells through targeted lipid nanoparticles, today announced that Capstan management will participate in the following upcoming investor conferences:

BMO Biopharma Spotlight Series: Novel Technologies for the Delivery of Genetic Medicines

Founding Chief Scientific Officer and Executive Vice President of R&D, Adrian Bot, M.D., Ph.D., will participate in a panel discussion titled “Novel LNPs Targeting Diverse Tissues” at 10:00 a.m. ET on Tuesday, March 28, 2023, at the virtual BMO Biopharma Spotlight Series: Novel Technologies for the Delivery of Genetic Medicines.

2^nd Annual Goldman Sachs Healthcare Disruption Conference

President and Chief Executive Officer, Laura Shawver, Ph.D., will attend the Goldman Sachs Healthcare Disruption Conference in New York City and will participate in a panel discussion titled “The Cell Therapy Re-Awakening” at 2:15 p.m. ET on Tuesday, April 4, 2023.

About Capstan (www.capstantx.com)

Capstan Therapeutics is a biotechnology company dedicated to advancing in vivo cell reprogramming. The core platform technology comprises proprietary targeted lipid nanoparticles (tLNPs) that are composed of LNPs conjugated with a recombinant protein binder, such as a monoclonal antibody. tLNPs are designed to deliver payloads, including mRNA or gene editing tools, capable of reprogramming specific cell types in vivo. The platform technology has the potential to generate transformative therapies with possible applications across a broad range of disease areas, including oncology, autoimmune disorders, fibrosis, and monogenic blood disorders. For more information, please visit www.capstantx.com and follow us on LinkedIn.

Contacts

Investors:

Miguel Arcinas

Vice President of Corporate Development

Capstan Therapeutics
[email protected]

Media:

Rhiannon Jeselonis

Ten Bridge Communications

[email protected]